
Cidara Therapeutics (CDTX) Stock Forecast & Price Target
Cidara Therapeutics (CDTX) Analyst Ratings
Bulls say
Cidara Therapeutics Inc. is positioned favorably due to the recent report of a strong influenza season, which could enhance the uptake of its clinical-stage asset, CD388, aimed at influenza prophylaxis. The company has also secured significant funding of $240 million in April 2024, enabling accelerated clinical development and leveraging their existing expertise with CD388 to further advance this asset. Additionally, the company's proprietary Cloudbreak platform, which includes DFCs targeting a range of diseases, positions Cidara favorably in the competitive landscape, potentially transforming treatment and preventative methods for serious diseases.
Bears say
Cidara Therapeutics, Inc. reported a substantial net loss of $52.4 million in 4Q24, indicating ongoing financial difficulties and a lack of profitability. The company's lead candidate, CD388, while demonstrating potent effects against influenza, suffers from poor oral bioavailability and fast renal clearance, raising concerns about its clinical viability. Additionally, the potential inability to secure acceptable partnerships further jeopardizes the prospects for successful commercialization, particularly in an environment where vaccine efficacy is heavily reliant on proper strain matching.
This aggregate rating is based on analysts' research of Cidara Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Cidara Therapeutics (CDTX) Analyst Forecast & Price Prediction
Start investing in Cidara Therapeutics (CDTX)
Order type
Buy in
Order amount
Est. shares
0 shares